Selected Articles from This Issue

Abstract

Highlights| February 01 2023 Selected Articles from This Issue Author & Article Information Online ISSN: 1538-8514 Print ISSN: 1535-7163 ©2023 American Association for Cancer Research2023American Association for Cancer Research Mol Cancer Ther (2023) 22 (2): 153. https://doi.org/10.1158/1535-7163.MCT-22-2-HI Related Content A commentary has been published: Retinoblastoma Expression and Targeting by CDK4/6 Inhibitors in Small Cell Lung Cancer A commentary has been published: High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer A commentary has been published: Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers View more A commentary has been published: Endo180 (MRC2) Antibody–Drug Conjugate for the Treatment of Sarcoma View less Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn MailTo Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record February 1 2023 Citation Selected Articles from This Issue. Mol Cancer Ther 1 February 2023; 22 (2): 153. https://doi.org/10.1158/1535-7163.MCT-22-2-HI Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search FolRα is a cell-surface glycoprotein that is frequently over-expressed in multiple cancer indications including ovarian and endometrial cancers, which are the most lethal cancers for female reproductive system. Here we reported the discovery of STRO-002, a homogeneous antibody-drug-conjugate (ADC) that binds to FolRα with high affinity, internalizes, and releases a novel tubulin-targeting cytotoxin (hemiasterlin) to kill FolRα expressing tumor cells. With superior stability and favorable pharmacokinetic (PK) profile, a single dose of STRO-002 induced significant tumor growth inhibition in xenograft and PDX models. Phase I studies for STRO-002 are in progress in ovarian and endometrial cancer patients (NCT03748186 and NCT05200364). Sarcomas comprise over 100 different subtypes which have significant genetic, morphological and histological heterogeneity, posing a substantial challenge to developing personalized therapies. Immunohistochemical staining identifies strong tumor cell expression of the recycling receptor, Endo180, in a high proportion of soft tissue sarcomas. Here, Evans and colleagues develop an antibody-drug conjugate... You do not currently have access to this content.